Your session is about to expire
← Back to Search
Engineered NK Cells for Recurrent Glioblastoma
Study Summary
This trial is to find out the benefits and side effects of using engineered natural killer cells to treat patients with recurrent glioblastoma.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 60 Patients • NCT00096226Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood counts meet the required levels for treatment.I have been treated with Gliadel wafers before.I have had cancer treatment directly into the tumor or nearby area.I have a lung condition not caused by an infection.I had radiation therapy less than 3 months ago, unless my cancer showed early progression.I agree to use two effective birth control methods during and for 3 months after the study.I have an immune system disorder or have taken drugs that weaken my immune system in the last week.My cancer is primarily in my brainstem, spinal cord, or has spread outside the brain.I have received treatment with drugs that target immune checkpoints.My tumor is larger than 5 cm.I am 18 years or older.I have HIV, HTLV1/2, active Hepatitis B or C, but not just from a vaccine.I have not received a live vaccine in the last 30 days.I have a bleeding or clotting disorder.I am on a full dose of blood thinners or medication to prevent blood clots.I haven't had chemotherapy or targeted therapy in the last 2 weeks, or I have mild neuropathy.It's been 12 weeks since my last radiation, or my cancer has grown despite treatment.My neurosurgeon believes my tumor can be removed with surgery.My liver tests are within normal limits.I have a tumor larger than 1cm2 that can be surgically removed.I am mostly able to care for myself and carry out normal activities.I have another cancer besides the one being studied, but it's either not growing or doesn't need treatment right now, except for certain skin cancers or cervical cancer that's been treated.I do not have an active infection needing strong medication that could affect my trial participation.My brain cancer has multiple distinct tumors that need separate treatment areas.I haven't needed strong medicine for an autoimmune disease in the last 3 months.I have had an organ transplant that requires me to take medicine to suppress my immune system.I had a brain MRI within the last 30 days.I had surgery over 3 weeks ago or a biopsy over a week ago and have recovered.I have a specific type of brain tumor that has come back after treatment.I am a woman who can have children and have a recent negative pregnancy test.I am using two birth control methods or am not having sex to join this study.My kidney function is within the normal range.
- Group 1: Group 1 (CB-NK-TGF-betaR2-/NR3C1- )
- Group 2: Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What security measures are in place to ensure patients' safety during Resection?
"Despite limited evidence of efficacy, our team at Power has assigned Resection a score of 1 due to the initial Phase 1 trial's data in support of safety."
How many individuals can potentially become part of this investigation?
"This medical trial has concluded its recruitment phase as of May 24th, 2022. If you're looking for alternative studies pertaining to glioblastoma or Resection, 1392 and 31 trials are filling their respective cohorts respectively."
Are there any opportunities for potential participants to join this research endeavor?
"Currently, this medical trial is not actively seeking patients. It was initially made available on August 31st 2022 and last modified on May 24th 2022. For those looking to join other clinical trials instead, 1392 studies recruiting individuals with glioblastoma are currently in progress while 31 Resection trials have open recruitment slots."
Has the medical community conducted any other investigations related to Resection?
"Currently, 31 ongoing clinical trials are studying Resection treatments with none of these studies in the third phase. While Wuxi, Jiangsu is where most investigations are taking place, there are 71 sites around the world running examinations on this subject matter."
Share this study with friends
Copy Link
Messenger